Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Publication Name: Breast Cancer Research and Treatment

Author(s): Laura J. van ‘t Veer; Christina Yau; Nancy Y. Yu; Christopher C. Benz; Bo Nordenskjöld; Tommy Fornander; Olle Stål; Laura J. Esserman; Linda Sofie Lindström;

Background Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negative patients … Continued